Antitumor Effects of Natural-Human TNF on BDFI Mice Bearing Lewis Lung Carcinoma

Natural-human tumor necrosis factor (n-TNF) was obtained by isolating and refining lymphokines which were extracted from human acute lymphoblastic leukemia BALL-I cells. Antitumor effects of this n-TNF were studied by using Lewis lung carcinoma (3LL) which was transplanted on BDFI mice. n-TNF showed inhibitory effects of the proliferation of metastatic tumors dose-dependently through i.v. injection daily for 10 days. And the study of the dose schedule of the administration and the route of the administration showed that routes of i.v., i.m. and i.t. injections were effective respectively through daily administration. Histological study showed effects which were ranked Grade Ilb (and partially III) of Shimosato and Ohboshi's histological criteria

The Synergistic Antitumor Effect of Natural-Human TNF and Anticancer Drugs

In the present report, we compared and discussed synergistic antitumor effects of natural-human tumor necrosis factor (n-TNF) which was derived from human acute lymphoblastic leukemia BALL-I cells and conventional anticancer drugs by using Lewis lung carcinoma which was transplanted on BDF1 mice. n-TNF and anticancer drugs were administered daily for 10 days. n-TNF showed antitumor effects which were equivalent to or stronger than MMC (1 mg/kg/day, i.v.), 5FU (5 mg/kg/day, i.v.), Adriamycin (1 mg/kg/day, i.v.), Actinomycin D (0.05 mg/kg/day, i.v.), Cyclophosphamide (10 mg/kg/day, i.v.) and OK-432 (0.5 KE/mouse/day, s.c.). And synergistic antitumor effects were observed when n-TNF was administered with anticancer drugs, and the strong enforcement was obtained especially when it was combined with 5FU

Synergistic Antitumor Effects of Natural Human Tumor Necrosis Factor and Mouse Interferon Beta and Gamma

Referring to synergistic antitumor effects of natural human tumor necrosis factor (n-TNF) derived from human acute lymphoblastic leukemia BALL-I cell as well as mouse interferon beta (mIFNbeta) and mouse interferon gamma (mIFNgamma), a series of the study was made using Lewis lung carcinoma grafted on BDF1 mice. With a combination dose of n-TNF (1 x 10^2 U/kg/day) and mIFNbeta (1 x 10^2 IU/kg/day) as well as that of n-TNF (1 x 10^2 U/kg/day) and mIFNgamma (1 x 10^2 IU/kg/day), a significant enhancement of antitumor effect was observed. Furthermore, with a triple combination dose of n-TNF (1 x 10^2 U/kg/day), mIFNbeta (I x 10^2 IU/kg/day) and mIFNgamma (I x 10^2 IU/kg/day), too, a strong synergistic effect was noted. The concentration of n-TNF required for concomitant use with mIFNbeta and mIFNgamma was 1 over 5 x 10^3 of that required for single dose of n-TNF, to obtain the same level of effect

Active enhancement of rat cardiac allografts induced by donor specific semisoluble antigens.

Active enhancement was induced in inbred rats with cardiac allografts using semisoluble antigens. The optimal time of antigen pretreatment and optimal dose of semisoluble antigens were examined. The presence of serum blocking factors in the sera of rats having had allografts for a long time was examined with a macrophage migration inhibition test and lymphocyte microcytotoxicity assay. Since the blocking factors of macrophage migration inhibition were increasing on the 7th day, that day was determined to be the optimal time of antigen pretreatment. The mean survival time (MST) of cardiac allografts in untreated rats was 17.2 +/- 7.5 days. Semisoluble antigens were administered at 2 mg/kg body weight 7 days before the graft, 4 mg/kg 7 days before the graft and 2 mg/kg divided over three days, 15, 8 and 1 day before the graft, and the MSTs of cardiac allografts of rats receiving these treatments were 71.2 +/- 39.9, 62.6 +/- 42.2 and 79.3 +/- 31.0 days, respectively. The MST in each group of the treated rats was significantly longer than that of the control group (p less than 0.01). Rejection of the allograft, however, was accelerated in a group treated with 8 mg/kg 7 days before the graft (MST: 8.4 +/- 3.2 days). Serum blocking factors were detected in the sera of approximately half of the rats having cardiac allografts which survived a long time.</p

The Clinical Significance of CT in the Preoperative Diagnosis of Colon and Rectal Cancer

The clinical significance of CT in the preoperative diagnosis of colon and rectal cancer was studied. Thirty four patients were investigated in this series. The diagnostic criteria of the CT examination were previously established in a study of wall invasion (S factor), lymph node metastasis (N factor), liver metastasis (H factor) and peritoneal dissemination (P factor). The CT diagnosis was done prospectively according to these criteria, and the CT diagnosis was compared with the macroscopic and histological diagnosis. The accuracy of the prospective diagnosis as to H, S, N and P factors was 79.4%, 55.9%, 41.2% and 20.6%, respectively. The diagnostic value of CT seemed to be acceptable as to the H factor, but limited to some extent to the S and N factors

Early diagnosis of acute renal allograft rejection: efficacy of macrophage migration inhibition test as an immunological diagnosis

1. Three cases of acute rejection were detected by macrophage migration inhibition tests (MIT) conducted directly on seven patients who had received renal allografts. The macrophage migration inhibitory factor (MIF) activity was positive in all cases 1-2 days before the appearance of acute rejection. 2. After the administration of a high dose of Solu-Medrol (1g/day for 3 days) to suppress the acute rejection, MIF activity recovered to its normal level 3 days later. These findings seem to indicate that MIT yields immunologically useful criteria for the early detection of an acute rejection.</p

Transplant Biology at a Crossroads: Surgeons can now give patients a new hand or even a new face, but they still can't provide any guarantees that the benefits are worth the risks.

Despite major advances in transplantation biology, allowing transplants not just of critical organs like heart and kidney but also of limbs and faces, researchers are still struggling to minimize the risks from achieving the level of immunosuppression needed to make the body accept foreign tissues

A Case of Colonic Metastasis of Breast Cancer Positive for Estrogen Receptor

This is the first report of a metastatic colon cancer of breast cancer positive for estrogen receptor. A 56-year-old woman who had undergone standard radical mastectomy due to right breast cancer was suffered from left lower abdominal pain. Barium enema and proctoscopy revealed a narrowing at the rectum and the descending colon. Needle biopsy of the rectum revealed Group 5. The resection of the left colon, the rectum and the ovaries were performed. Foci were macroscopically present at the rectum, the sigmoid colon and the descending colon. Histological examination revealed that colonic foci were metastases from the breast cancer of lobular carcinoma. The colonic preparation was positive for estrogen receptor